Sudarshan Pharma Industries Allots 90 Lakh Shares to Promoters

Sudarshan Pharma Industries Ltd approved the allotment of 90 lakh equity shares to promoter-category holders on June 12, 2026, following conversion of 9 lakh preferential warrants. The conversion followed receipt of Rs 11.46 crore, representing 75% of the warrant issue price, and raised the promoter group's holding to 58.93% from 26.6%.

Why did Sudarshan Pharma Industries allot 90 lakh shares to promoters?

Sudarshan Pharma Industries made the allotment after its Warrants Committee approved the conversion of 9 lakh warrants issued to promoters on a preferential basis. The committee's decision was disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Each warrant entitled its holder to receive 10 equity shares of face value Re 1 each. This entitlement reflected the company's stock split, resulting in 90 lakh new equity shares being allotted upon conversion. The shares were allotted to persons belonging to the promoter category.

The Director's Report states that the promoters paid Rs 11.46 crore, or 75% of the warrant issue price, before the conversion was approved. The warrants had been issued at Rs 169.83 each, while the conversion structure resulted in an effective issue price of Rs 16.983 per equity share after accounting for 10 shares against every warrant.

The newly allotted equity shares rank pari-passu with Sudarshan Pharma's existing equity shares. This means they carry the same rights as existing shares, subject to the applicable terms of issue and listing requirements.

What were the key details of the warrant conversion?

The conversion involved 9 lakh warrants and resulted in the issue of 90 lakh equity shares of Re 1 each. Sudarshan Pharma's Warrants Committee approved the transaction at its meeting held on June 12, 2026, after an earlier committee meeting had been scheduled to consider warrant conversion and allotment.

The company said the warrants were issued under the framework in Chapter V of the SEBI Issue of Capital and Disclosure Requirements Regulations, 2018. Under the disclosed terms, a warrant holder could apply for 10 equity shares against each warrant held, subject to the conditions and timeline specified by the company.

The company subsequently applied to BSE for listing of the 90 lakh shares. BSE approved the listing application on August 3, 2026, according to the Director's Report. Sudarshan Pharma also initiated corporate action to credit the shares to the allottees' demat accounts.

How did the allotment change Sudarshan Pharma's promoter holding?

The allotment increased the promoter group's stake in Sudarshan Pharma to 58.93% from 26.6%, based on the disclosed post-allotment shareholding figures. The increase followed the conversion of warrants held by two promoter directors into equity shares.

A preferential warrant conversion changes the company's outstanding equity share base because new shares are issued to warrant holders. In this case, the promoter group's holding rose as 90 lakh shares were issued to promoter-category allottees. The company has stated that these shares rank on an equal basis with existing equity shares.

For investors, the reported shareholding change is relevant because it alters the ownership composition following the conversion. The disclosure identifies the allotment as a promoter-category transaction and records the share count, conversion terms and funds received before the equity issue.

The BSE listing approval addresses the listing of the newly issued shares. Sudarshan Pharma said it had initiated the process to credit the shares into demat accounts and that it would apply for trading approval from BSE thereafter. The disclosed sequence distinguishes listing approval from the subsequent trading approval process.

What other funding proposals has Sudarshan Pharma disclosed?

Sudarshan Pharma separately informed BSE that its board would consider a fundraising proposal at a meeting scheduled for June 18, 2026. The proposed methods included private placement, preferential issue, or one or more other instruments, subject to necessary statutory and regulatory approvals.

The company had also been reported as considering fundraising through equity, convertibles, warrants or debt. Separately, an announcement referred to a plan to raise Rs 188 crore through a preferential issue and issue 4.3 crore fully convertible warrants. The provided disclosures do not establish that these referenced proposals formed part of the June 12 warrant conversion.

The June 12 transaction was specifically an allotment arising from the exercise of previously issued warrants. It should therefore be viewed separately from the board's later consideration of potential fundraising routes, unless the company provides a disclosure linking the transactions.

Sudarshan Pharma also disclosed a board meeting scheduled for October 29, 2026, to consider unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, along with a fundraising plan. The disclosure did not provide the outcome of that meeting.

What does the warrant conversion mean for investors and trading?

The warrant conversion increases Sudarshan Pharma's issued equity capital by 90 lakh shares and materially changes the disclosed promoter-group ownership level. The allotment was made after the company received the stated 75% amount due under the warrant terms, providing the documented basis for the conversion.

The shares cannot be treated as freely tradable solely on the basis of their allotment because the company said it would seek BSE trading approval after completing the credit of shares to allottees' demat accounts. BSE's August 3 approval covered the company's application for listing of the additional shares.

The transaction also places the company's capital-raising disclosures in focus. A preferential allotment and any further issue of equity-linked instruments can affect the number of shares outstanding and ownership distribution. The available disclosures identify the proposed routes for fundraising but do not provide final terms for any separate future issue.

Conclusion

Sudarshan Pharma converted 9 lakh promoter-held warrants into 90 lakh equity shares after receiving Rs 11.46 crore, lifting the promoter group's disclosed holding to 58.93%. The conversion was approved by the Warrants Committee on June 12, 2026, and the company later received BSE approval for listing the additional shares.

The next disclosed steps are the credit of shares to the allottees' demat accounts and an application for BSE trading approval. Investors may also track the company's disclosed fundraising proposals, including matters placed before the board, for any final issue terms or regulatory approvals.